Chinatsu Sakata-Sakurai
Company: Astellas Pharma
Job title: Vice President, Primary Focus Lead, Targeted Protein Degradation, Astellas
Seminars:
Panel : Debating the Therapeutics Utility of PROTACs & Molecular Glues versus Direct Targeting of RAS to Strategies Best-in-Class Therapeutic Interventions 12:15 pm
day: Day Two Track A AM